Fundraising FoxJanus Henderson Investors — 2025 Investments
9 investments dated 2025 · listed companies and verified rows first · show all
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.+9 more
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsEnavate SciencesLifeSci Venture PartnersRA CapitalBAM ElevatePatient Square Capital
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtechBothell, US
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalHBM Healthcare InvestmentsHercules Capital, Inc.MedicxiOrbiMedRA Capital+1 more
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsGilmartin Capital LLCSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge Group+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeFuture Positive CapitalGalvanize Climate SolutionsAlly Bridge GroupFidelity Investments+5 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Co-investorsLifebloodNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLC+3 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesViking Global+11 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.